Morari Launches Study to Explore MOR's Impact on Ejaculation Intensity
New findings may expand clinical and commercial potential of FDA cleared MOR product
Originally developed and cleared by the FDA in
"Many medical innovations uncover unexpected benefits beyond their original intent," said
The upcoming study will enroll male volunteers who will share their experiences, helping Morari assess MOR's potential dual benefit: delaying ejaculation and enhancing pleasure.
Dr.
"MOR's neuromodulation mechanism aligns with what we know from other nerve stimulation applications, where sensory feedback can be enhanced. If these results hold, MOR could become a breakthrough, non-pharmaceutical option for improving sexual satisfaction and intimacy."
If validated, the study could further position MOR as a first-of-its-kind wearable device that not only delays ejaculation but enhances pleasure, redefining male sexual wellness.
For more information about MOR or to inquire about study participation, visit: https://www.yourmor.com.
About Morari, Inc.
Morari, Inc. is a sexual health and wellness company focused on restoring confidence and intimacy through innovative, drug-free solutions. Its first product, MOR, is an FDA-cleared, app-enabled wearable patch designed to enhance and improve sexual performance.
Media Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/morari-launches-study-to-explore-mors-impact-on-ejaculation-intensity-302520981.html
SOURCE Morari, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- aphranel® Hosts European Physicians in China for Clinical Exchange
- Stora Enso's Board of Directors approves demerger plan to separate Bergslagets Skogar into a new listed company, announcing strategic targets and dividend policy
- New clinical data on lecanemab to be presented at CTAD conference 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share